Latest filing published 09 Feb 2026 for 프리시젼바이오.
광동제약: trading record in brief
광동제약 discloses dealings in 프리시젼바이오 to DART (FSS). In total, 9 filings cover trades dated from 13 June 2022 to 9 February 2026.
Every open-market trade on record is a purchase: 8 purchases, and no sale. The totals do not cover 8 filings with an undisclosed amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. In 2026 alone, the filings show 2 purchases and no sales.
None of the 6 purchases we analysed coincided with buying by another insider of the same company within 30 days.
The record was last updated on 9 February 2026 with an open-market purchase in 프리시젼바이오. Typically, a trade is published a median of 4 days after it takes place. Until a filing is published, the market cannot know about the trade. This summary is built from DART (FSS) disclosures alone and does not predict where the share price will go.
Companies and markets linked to 광동제약
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- ShareKRXDART:20260209000672Canonical exit: 10 May 2026 (T+90)
- 1,197,269 sharesKRXDART:20260209000660Canonical exit: 10 May 2026 (T+90)
- ShareKRXDART:20241010000581Canonical exit: 8 Jan 2025 (T+90)
- 0KRXDART:20241010000567
- 3,449,732 sharesKRXDART:20240705000420Canonical exit: 3 Oct 2024 (T+90)
- 3,449,732 sharesKRXDART:20231121000243Canonical exit: 19 Feb 2024 (T+90)
- 3,449,732 sharesKRXDART:20220613000118Canonical exit: 11 Sept 2022 (T+90)
9 of 9 declarations